MRI for Assessment of Hypoxia-Induced Prostate Cancer Aggressiveness (FuncProst)

The recruitment status of this study is unknown because the information has not been verified recently.
Verified October 2011 by Oslo University Hospital.
Recruitment status was  Recruiting
Sponsor:
Collaborator:
Radboud University
Information provided by (Responsible Party):
Therese Seierstad, Oslo University Hospital
ClinicalTrials.gov Identifier:
NCT01464216
First received: October 31, 2011
Last updated: November 2, 2011
Last verified: October 2011

October 31, 2011
November 2, 2011
October 2011
December 2013   (final data collection date for primary outcome measure)
Not Provided
Not Provided
Complete list of historical versions of study NCT01464216 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
MRI for Assessment of Hypoxia-Induced Prostate Cancer Aggressiveness
Not Provided

The purpose of the study is to combine and correlate data from morphological and functional MRI, molecular signatures of tumor hypoxia, the presence of micrometastases and tumor hypoxia with the goal being predicting of prostate cancer aggressiveness.

Not Provided
Observational
Observational Model: Cohort
Time Perspective: Prospective
Not Provided
Retention:   Samples With DNA
Description:

Blood, bone marrow, lymph nodes, prostate tissue

Non-Probability Sample

Prostate cancer patients referred for surgical treatment.

  • Prostatic Neoplasms
  • Genital Neoplasms, Male
  • Prostatic Diseases
Not Provided
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
180
Not Provided
December 2013   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Patients suitable for surgery with confirmed prostate cancer, Gleason grade ≥ 3
  • Patient has received no prior treatment for prostate cancer.
  • Patient has adequate renal function: Estimated creatinine clearance ≥ 60 ml/minute.
  • Patient must sign written informed consent according to the protocol approved by the Regional Ethics Committee.

Exclusion Criteria:

  • Patient with contraindication to MR or MR contrast media according to clinical practice.
  • Patients who want to withdraw for any reason during the study.
  • Patients previously undergone pelvic surgery or radiation therapy
Male
Not Provided
No
Norway
 
NCT01464216
REK-2010/1656
No
Therese Seierstad, Oslo University Hospital
Oslo University Hospital
Radboud University
Not Provided
Oslo University Hospital
October 2011

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP